International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 23s, 2025
https://theaspd.com/index.php

Hydrogel-Based Nanoparticles Drug Delivery Systems for Antifungal Therapy: A Smart Approach to Targeted Treatment

Dr. S. Amudha[1], M. Srinath[2]
[1]Associate Professor, School of Pharmacy, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu - 600119
[2]M. Pharm, Department of Pharmaceutics, School of Pharmacy, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu - 600119

ABSTRACT
Fungal infections remain a serious global health concern, ranging from superficial mycoses to invasive systemic diseases with high morbidity and mortality. Despite the availability of antifungal drugs, therapeutic outcomes are often compromised by poor solubility, limited bioavailability, systemic toxicity, and emerging drug resistance. To address these challenges, nanotechnology and biomaterial sciences have introduced hydrogel-based nanoparticle systems as advanced drug delivery platforms. These hybrid systems integrate the biocompatibility, high-water retention, and stimuli responsiveness of hydrogels with the protective encapsulation, targeting, and controlled release capabilities of nanoparticles. Such delivery systems enhance antifungal efficacy by enabling site-specific and sustained drug release, reducing systemic side effects, and overcoming fungal resistance mechanisms. This review consolidates recent progress in the design and application of hydrogel–nanoparticle composites for antifungal therapy, highlighting their mechanisms, therapeutic advantages, case studies, limitations, and future perspectives. By bridging conventional antifungal pharmacology with smart biomaterials, hydrogel-based nanoparticles represent a transformative strategy in combating fungal infections.
Keywords: *Hydrogels, Nanoparticles, Antifungal therapy, Smart drug delivery, Controlled release, Amphotericin B, Fluconazole, Nanocomposites*

1. INTRODUCTION

Fungal infections affect millions of people worldwide, ranging from superficial conditions such as dermatophytosis and candidiasis to life-threatening systemic infections caused by Candida, Aspergillus, Cryptococcus, and emerging multidrug-resistant fungi. Immunocompromised individuals, including patients with cancer, HIV/AIDS, organ transplants, or long-term antibiotic therapy, are especially vulnerable to invasive fungal diseases. According to the World Health Organization (WHO), invasive fungal infections are associated with mortality rates of up to 50% in high-risk groups, underscoring the urgent need for safer and more effective antifungal therapies.

Conventional antifungal agents—including polyenes (amphotericin B, nystatin), azoles (fluconazole, itraconazole, voriconazole), and echinocandins (caspofungin, micafungin)—have contributed significantly to clinical management. However, their therapeutic success is often restricted by low aqueous solubility, poor bioavailability, rapid metabolism, systemic toxicity, and increasing drug resistance. For instance, amphotericin B is highly effective but notorious for nephrotoxicity, while azoles face resistance due to efflux pumps and target enzyme mutations in fungi.

To overcome these drawbacks, novel drug delivery systems (DDSs) have been explored. Among them, hydrogels—three-dimensional hydrophilic polymeric networks—have attracted attention for their high water retention, biocompatibility, tunable porosity, and ability to sustain drug release. Similarly, nanoparticles (NPs) provide encapsulation of poorly soluble antifungals, enhanced cellular uptake, and the potential for surface modification to achieve targeted delivery.

By combining these two platforms, hydrogel-based nanoparticles have emerged as hybrid smart systems capable of:

- Encapsulating antifungal drugs with enhanced solubility and stability.
- Achieving localized, sustained, and stimuli-responsive drug release.
- Reducing systemic toxicity through targeted delivery.
- Overcoming resistance by bypassing fungal defense mechanisms.

This review focuses on the fundamentals, applications, and recent advances of nanoparticle–hydrogel composites for antifungal therapy, discussing mechanisms of action, therapeutic outcomes, challenges, and future perspectives.

2. FUNDAMENTALS

2.1 Hydrogels as Drug Delivery Platforms

Hydrogels are crosslinked polymeric structures capable of absorbing large amounts of water while maintaining mechanical integrity. Their resemblance to natural extracellular matrices and ability to encapsulate both hydrophilic and hydrophobic drugs make them highly attractive for biomedical applications. Hydrogels can be synthesized from natural polymers (chitosan, alginate, gelatin, hyaluronic acid) or synthetic polymers (polyvinyl alcohol, polyethylene glycol, poly(N-isopropylacrylamide) [PNIPAM]).

One of their most important features is stimuli responsiveness. "Smart" hydrogels can alter their swelling, porosity, and release behavior in response to environmental triggers such as pH, temperature, ionic strength, enzymes, or redox conditions. For example:

pH-sensitive hydrogels release antifungal drugs preferentially in the acidic microenvironment of infected tissues.

Thermosensitive hydrogels undergo sol-to-gel transition at body temperature, making them suitable for injectable depot formulations.

Despite these benefits, traditional hydrogels face limitations including poor mechanical stability, low loading of hydrophobic antifungal drugs, and premature drug leakage. These drawbacks have paved the way for integrating nanoparticles into hydrogel matrices.

2.2 NANOPARTICLES IN ANTIFUNGAL DRUG DELIVERY

Nanoparticles, typically ranging from 10–500 nm, have revolutionized drug delivery by improving solubility, enhancing bioavailability, and enabling targeted release. For antifungal therapy, nanoparticles help overcome poor drug absorption, systemic toxicity, and drug resistance.

Types of nanoparticles commonly used in antifungal delivery include:

- **Polymeric nanoparticles (PLGA, chitosan):** Biodegradable, high encapsulation efficiency, suitable for sustained release of drugs like fluconazole.
- **Lipid-based nanoparticles:** (liposomes, solid lipid nanoparticles, nanostructured lipid carriers): Amphotericin B liposomes are already in clinical use, reducing nephrotoxicity compared to conventional formulations.
- **Inorganic nanoparticles:** (silver, zinc oxide, iron oxide): Exhibit intrinsic antifungal properties, enhance synergistic effects when combined with drugs.
- **Hybrid nanoparticles:** Combine organic and inorganic materials for multifunctional delivery.

Surface modification with ligands or antibodies allows nanoparticles to actively target fungal cells or infected tissues, improving therapeutic selectivity.

2.3 NANOPARTICLE-EMBEDDED HYDROGELS: A HYBRID APPROACH

Integrating nanoparticles into hydrogels results in nanocomposite hydrogels, which unite the structural stability and stimuli responsiveness of hydrogels with the encapsulation and controlled release capabilities of nanoparticles.

Key strategies include:

1. In situ synthesis of nanoparticles within hydrogels – e.g., silver nanoparticles generated inside chitosan hydrogels for antifungal wound dressings.
2. Physical entrapment of pre-formed nanoparticles – e.g., liposomal amphotericin B incorporated into injectable hydrogel matrices.
3. Surface tethering of nanoparticles onto hydrogel backbones – enhancing mechanical stability and sustained release.

Advantages for antifungal therapy:

- Prolonged and controlled drug release.
- Protection of drugs from hydrolysis or degradation.
- Improved loading of hydrophobic antifungals.
- Targeted delivery at infection sites (skin, mucosa, systemic).
- Synergistic antifungal activity when nanoparticles themselves have antimicrobial properties.

3. ANTIFUNGAL THERAPY VIA HYDROGEL–NANOPARTICLE SYSTEMS

The management of fungal infections requires safe, effective, and site-specific delivery of antifungal drugs.

Hydrogel–nanoparticle composites provide a versatile solution by combining the protective encapsulation and controlled release of nanoparticles with the biocompatibility and stimuli responsiveness of hydrogels. Recent advances highlight their application for polyene antifungals, azoles, echinocandins, and novel antifungal agents.

3.1 POLYENE ANTIFUNGALS

1. Amphotericin B (AmB)

Amphotericin B is considered the "gold standard" for systemic fungal infections but is limited by low solubility and dose-dependent nephrotoxicity.

- **Hydrogel–liposomal AmB:** Liposomal nanoparticles of AmB incorporated into hydrogel matrices provide sustained release with reduced renal toxicity. In animal models, hydrogel depots allowed localized therapy for Candida infections.
- **AmB–chitosan nanohydrogel:** Chitosan-based hydrogels embedded with AmB nanoparticles enhanced drug solubility and improved antifungal activity against Candida albicans.
- **AmB–silver nanoparticle hydrogels:** Silver nanoparticles offer intrinsic antifungal activity. When embedded with AmB in alginate–chitosan hydrogels, synergistic inhibition of resistant strains was reported.

2. Nystatin

- Topically used for oral and vaginal candidiasis, nystatin faces stability issues.
- Nystatin-loaded lipid nanoparticles embedded in hydrogels enhanced drug retention at mucosal sites and improved patient compliance.

3.2 AZOLE ANTIFUNGALS

1. Fluconazole

Widely prescribed due to oral bioavailability but limited by resistance and rapid clearance.

- Fluconazole–polymeric nanoparticle hydrogels: PLGA nanoparticles embedded in pH-sensitive hydrogels enabled sustained release in acidic vaginal environments, improving treatment of vulvovaginal candidiasis.
- Thermosensitive fluconazole hydrogels: Chitosan–PNIPAM hydrogels loaded with fluconazole nanoparticles formed gels at body temperature, providing prolonged antifungal activity with fewer doses.

2. Itraconazole and Voriconazole

Both have poor solubility and variable bioavailability.

- Itraconazole nanostructured lipid carriers in hydrogels: Improved solubility, skin penetration, and antifungal activity against dermatophytes.
- Voriconazole–nanogel composites: Injectable hydrogels embedding voriconazole-loaded nanoparticles allowed localized delivery in ocular fungal infections, reducing systemic exposure.

3. Posaconazole

Effective against resistant strains but hindered by poor solubility.

- Nanoparticle-loaded hydrogels increased its stability and provided controlled release for systemic therapy in animal studies.

3.3 ECHINOCANDINS

Echinocandins (caspofungin, micafungin, anidulafungin) are effective against Candida but must be administered intravenously due to poor oral bioavailability.

- **Hydrogel–nanoparticle carriers** allow sustained local delivery, reducing systemic toxicity. For example, caspofungin nanoparticles embedded in hydrogels have shown promise in localized treatment of invasive candidiasis in animal infection models.

3.4 OTHER ANTIFUNGAL AGENTS

- **Terbinafine-loaded nanohydrogels:** enhanced transdermal delivery for dermatophytic infections, overcoming poor skin penetration of conventional creams.
- **Eberconazole–lipid nanoparticle hydrogels:** demonstrated higher efficacy for topical dermatophyte infections.
- **Clotrimazole–silver nanoparticle:** hydrogels combined the broad-spectrum activity of clotrimazole with intrinsic antifungal properties of silver, reducing resistance development.

3.5CASE STUDIES AND RECENT ADVANCES:

- **Amphotericin B Lipid Nanoparticles in Hydrogels:** Demonstrated reduced kidney toxicity and improved efficacy in systemic candidiasis models (2023).
- **Fluconazole–nanogel vaginal formulations:** Provided prolonged retention and enhanced cure rates for recurrent vulvovaginal candidiasis (2024).
- **Itraconazole–nanoparticle hydrogels for skin infections:** Improved penetration into keratinized tissues, leading to faster recovery from dermatophytosis (2022).
- **Voriconazole nanocomposite hydrogels in ophthalmic use:** Enhanced corneal permeability and sustained antifungal activity in fungal keratitis (2021).
- **Terbinafine–lipid nanoparticle hydrogels:** Showed superior antifungal action against resistant Trichophyton species compared to marketed creams (2024).

3.6SUMMARY OF SELECTED STUDIES

Antifungal Drug	Nano Particle Type	Hydrogel Matrix	Application	Key Findings
Amphotericin B	Liposomes, polymeric NPs	Chitosan/alginate hydrogel	Systemic candidiasis	Reduced nephrotoxicity, sustained release
Fluconazole	PLGA nanoparticles	pH/thermosensitive hydrogel	Vaginal candidiasis	localized, prolonged activity
Itraconazole	Lipid NPs	Carbopol hydrogel	Skin Infections	Enhanced solubility & penetration
Voriconazole	Polymeric NPs	Injectable hydrogel	Ocular keratitis	Sustained drug release, reduced systemic dose
Terbinafine	Lipid/polymeric NPs	Chitosan-based hydrogel	Dermatophytosis	Improved transdermal absorption
Clotrimazole	Silver NPs	Alginate/chitosan hydrogel	Resistant fungal infections	Synergistic antifungal effect

4. MECHANISMS OF DRUG DELIVERY AND SMART RELEASE

The effectiveness of hydrogel–nanoparticle systems in antifungal therapy is determined by their ability to release the drug at the right site, at the right time, and at a controlled rate. Unlike conventional dosage forms, these hybrid systems combine the nanoparticles' drug-encapsulation capacity with the hydrogel's diffusion and stimuli-responsive properties, offering site-specific, sustained, and intelligent drug release.

4.1 DIFFUSION-CONTROLLED RELEASE

- One of the primary mechanisms is Fickian diffusion, where antifungal molecules diffuse from nanoparticles through the hydrogel network into surrounding tissues.
- The mesh size of the hydrogel and the drug–polymer interactions govern the release rate.

Example: Fluconazole-loaded PLGA nanoparticles in a hydrogel exhibited slow diffusion, maintaining therapeutic levels in the vaginal cavity for extended durations, reducing frequent dosing.

✓ Amphotericin B nanoliposomes in hydrogels showed a controlled diffusion pattern, preventing drug "burst release" and minimizing toxicity.

4.2 SWELLING- AND DEGRADATION-CONTROLLED RELEASE

- Hydrogels absorb biological fluids and swell, enlarging their pore size and allowing nanoparticles and drugs to be released gradually.
- Swelling-controlled release is useful in mucosal infections, such as vaginal or oral candidiasis, where body fluids trigger hydrogel expansion.
- Biodegradable hydrogels (e.g., chitosan, alginate, gelatin) undergo enzymatic degradation, leading to slow and sustained release of antifungals.

Example: Itraconazole-loaded nanocarriers embedded in chitosan hydrogels released drug gradually over 72 hours due to hydrogel swelling and polymer breakdown.

4.3 STIMULI-RESPONSIVE (SMART) RELEASE

Smart hydrogel–nanoparticle composites can respond to internal or external stimuli, ensuring spatiotemporal control of antifungal release.

a) pH-Responsive Systems:

- Fungal infection sites often present an acidic microenvironment due to inflammation and microbial activity.
- Fluconazole-loaded hydrogels released the drug faster at acidic pH (vaginal candidiasis models) compared to neutral pH, providing site-specific therapy.
- Amphotericin B nanogels showed preferential release in acidic tissues, reducing off-target toxicity.

b) Temperature-Responsive Systems:

- Thermosensitive hydrogels remain liquid at room temperature but gel at body temperature (37 °C), forming an in-situ depot.
- Voriconazole thermosensitive nanohydrogel formed a gel on ocular surfaces, prolonging drug retention against fungal keratitis.
- Such systems are particularly advantageous for injectable antifungal depots.

c) Enzyme-Responsive Systems:

- Infected tissues often exhibit higher levels of hydrolytic enzymes, which can degrade hydrogel crosslinks and trigger drug release.
- Example: Hydrogels crosslinked with matrix metalloproteinase-sensitive linkages released Amphotericin B nanoparticles specifically in infected tissues where enzyme levels were elevated.

d) Redox-Responsive Systems:

- High glutathione (GSH) levels in infected or inflamed tissues can cleave disulfide bonds within hydrogels.
- Redox-sensitive hydrogels loaded with itraconazole nanoparticles achieved site-specific release in inflamed skin, minimizing systemic exposure.

e) Magnetic- and Light-Responsive Systems:

- Magnetic nanoparticles (Fe_3O_4) embedded in hydrogels enable on-demand release of antifungals when exposed to an external magnetic field.
- Gold or silver nanoparticles can mediate photothermal effects under near-infrared (NIR) light, releasing antifungal drugs while exerting additional antimicrobial action.

Example: Clotrimazole–AgNP hydrogels showed enhanced antifungal efficacy with light-triggered release and intrinsic silver activity.

4.4 ADVANTAGES OF SMART RELEASE MECHANISMS

- Targeted antifungal delivery at infection sites (skin, mucosa, ocular tissues, systemic reservoirs).
- Reduced systemic toxicity, particularly relevant for nephrotoxic drugs like amphotericin B.
- Sustained drug levels, reducing frequent dosing and improving patient compliance.
- Overcoming resistance, as controlled drug exposure avoids subtherapeutic concentrations that promote fungal adaptation.
- Potential for combination therapy, where dual triggers (e.g., pH + temperature) can be engineered for more precise control.

5. ADVANTAGES AND CHALLENGES

Hydrogel–nanoparticle composites represent a significant advancement over conventional antifungal formulations. Their synergistic combination of controlled release, biocompatibility, and site-specific targeting helps overcome many drawbacks of traditional therapies. However, despite their promise, challenges in formulation, stability, toxicity, and regulatory acceptance remain.

5.1 ADVANTAGES

1. Enhanced Stability of Antifungal Agents;

- Hydrogels protect sensitive antifungal drugs from degradation due to hydrolysis, oxidation, or light exposure.

- Nanoparticles further stabilize poorly soluble antifungals such as itraconazole and amphotericin B.

2. Improved Solubility and Bioavailability;

- Nanoparticles improve the solubility of hydrophobic antifungals.
- Hydrogel matrices ensure sustained drug presence at infection sites, enhancing systemic absorption where needed.

3. Controlled and Site-Specific Release;

- Smart hydrogel systems release drugs in response to pH, enzymes, temperature, or light, ensuring drug release only at infection sites.
- Prevents premature release and minimizes systemic toxicity.

4. Reduced Toxicity and Side Effects;

- Amphotericin B-loaded nanogels reduce nephrotoxicity compared to free drug formulations.
- Localized delivery minimizes systemic exposure to toxic antifungals.

5. Versatility of Administration Routes;

- Suitable for oral, injectable, ocular, transdermal, and vaginal drug delivery.
- Adaptable to both systemic and localized fungal infections.

6. Synergistic Antifungal Action;

- Metallic nanoparticles (e.g., silver, zinc oxide) possess intrinsic antifungal properties, complementing drug activity.
- Dual-action systems help reduce fungal resistance.

5.2 CHALLENGES:

1. Scale-Up and Manufacturing Issues;

- Maintaining uniform nanoparticle size and distribution within hydrogels is difficult in large-scale production.
- Variability in polymer crosslinking can affect drug release profiles.

2. Complex Formulation Optimization;

- Requires balancing drug loading, release kinetics, hydrogel crosslinking, and nanoparticle stability.
- Complex designs increase production costs.

3. Stability and Storage Concerns;

- Long-term storage may cause microbial contamination, aggregation of nanoparticles, or changes in hydrogel structure.
- Lyophilization techniques sometimes alter hydrogel properties.

4. Toxicity and Biocompatibility Issues;

- Some nanoparticles (e.g., silver, ZnO) may cause oxidative stress and cytotoxicity in host tissues at higher doses.
- Ensuring safe biodegradation of synthetic hydrogel polymers is necessary.

5. Regulatory Barriers;

- Herbal and synthetic antifungal formulations already face strict regulatory scrutiny.
- Nanotechnology-based systems require additional safety, stability, and clinical validation data before approval.

6. Translational Gap;

- Most studies are limited to in vitro and animal models.
- Lack of robust clinical trials delays entry into mainstream medical practice.

5.3COMPARSION: CONVENTIONAL ANTI FUNGAL THERAPY VS HYDROGEL -NANO PARTICLE SYSTEMS

Aspects	Conventional Therapy	Hydrogel -Nanoparticle Systems
Solubility	Poor (e.g., Amphotericin B, itraconazole)	Enhanced via nanoparticle encapsulation
Bioavailability	Variable, often low	Improved systemic absorption & site-specific retention
Toxicity	High systemic toxicity (nephrotoxicity, hepatotoxicity)	Reduced systemic side effects via localized delivery
Drug Release	Rapid, uncontrolled	Controlled, sustained, and stimuli-responsive

Dosing Frequency	Frequent dosing required	Extended release reduces frequency
Resistance Development	Common due to subtherapeutic levels	Maintained drug concentration reduces resistance risk
Versatility	Limited routes (oral, IV, topical)	Multi-route applicability (oral, injectable, ocular, vaginal, transdermal)
Stability	Degradation under physiological conditions	Hydrogels protect drugs from chemical/enzymatic breakdown
Clinical Use	Established, FDA-approved drugs	Emerging, still under preclinical/early clinical research

6. FUTURE PERSPECTIVES

Hydrogel–nanoparticle composites have shown remarkable potential in antifungal therapy by enhancing drug stability, targeting, and controlled release. However, translating this technology from laboratory research to clinical and commercial use requires addressing several scientific, technological, and regulatory challenges. The following future directions outline critical areas for development and innovation.

6.1 Green and Sustainable Nanoparticle Synthesis;

- The conventional synthesis of nanoparticles often involves hazardous chemicals and solvents, raising environmental and safety concerns. Green synthesis methods, such as using plant extracts, polysaccharides, or microbial metabolites, offer sustainable alternatives that reduce toxicity and improve biocompatibility
- Plant-based reducing agents like polyphenols, flavonoids, and terpenoids can simultaneously serve as stabilizers and bioactive agents in nanoparticle synthesis.
- Green methods also integrate antifungal phytoconstituents during particle formation, potentially enhancing therapeutic efficacy and reducing side effects.

6.2 Multi-Stimuli-Responsive Hydrogels;

- Most current systems are designed to respond to a single trigger, such as pH or temperature. However, infectious microenvironments exhibit multiple abnormal cues, including acidic pH, high enzyme activity, and elevated glutathione levels.
- Designing hydrogels that respond to pH + enzyme, or temperature + redox changes, can allow more precise and sequential drug release.
- Multi-stimuli systems offer better control, particularly in complex infections where fungal biofilms, immune reactions, and altered tissue metabolism coexist.

6.3 Personalized and Precision Antifungal Therapy;

- Fungal infections vary based on patient-specific factors such as immune status, genetics, metabolic rate, and co-existing diseases.
- Integrating hydrogel–nanoparticle systems with personalized medicine approaches can tailor drug release profiles to individual needs.
- Advances in biomarker identification and diagnostic tools may allow real-time modulation of antifungal dosing based on infection progression or patient response.

6.4 Advanced Manufacturing Technologies;

- Emerging fabrication techniques, including 3D bioprinting, microfluidics, and electrospinning, offer opportunities to engineer hydrogels with spatially defined structures and gradient drug distribution.
- Customized implants, wound dressings, or injectable gels can be fabricated with precise mechanical and release properties.
- Scalable processes such as continuous flow synthesis and modular assembly can enhance reproducibility and reduce manufacturing costs.

6.5 Clinical Translation and Regulatory Frameworks;

- Although preclinical studies are promising, widespread adoption requires systematic validation through:
- Large-scale production with consistent quality and performance metrics.
- In vivo toxicity and long-term stability studies, especially in human-relevant models.
- Well-designed clinical trials to assess efficacy, safety, and pharmacokinetics.

- Development of standardized guidelines by regulatory agencies for herbal nanomedicines and polymer-based drug carriers.

Collaborations between academic research institutions, pharmaceutical companies, and regulatory bodies will be vital to overcome these hurdles and bring these advanced antifungal therapies to market.

6.6 Schematic Future Roadmap (Forvisualization/Figure)

You may design the following figure to summarize the path toward clinical application:

Lab → Preclinical → Clinical Trials → Regulatory Approval → Industrial Scale-up → Market Adoption

Where each phase includes:

1. Lab Research → Material selection, nanoparticle synthesis, antifungal drug loading.
2. Preclinical Studies → In vitro antifungal tests, toxicity assays, animal infection models.
3. Clinical Trials → Phase I safety, Phase II efficacy, Phase III large-scale trials.
4. Regulatory Approval → Stability testing, GMP production, regulatory submissions.
5. Industrial Scale-up → Manufacturing consistency, cost optimization, supply chain management.
6. Market Adoption → Clinical deployment, patient education, integration into treatment protocols.

7. CONCLUSION

Fungal infections continue to pose a significant clinical challenge worldwide, especially in immunocompromised populations where conventional antifungal therapies are often limited by poor solubility, systemic toxicity, and emerging drug resistance. Hydrogel–nanoparticle composites have emerged as a promising and versatile platform that integrates the protective and responsive properties of hydrogels with the encapsulation, targeting, and controlled release capabilities of nanoparticles.

This review has highlighted how these hybrid systems enhance the therapeutic potential of antifungal agents such as amphotericin B, fluconazole, itraconazole, and voriconazole, among others. By improving drug stability, bioavailability, and site-specific release, these systems provide sustained therapeutic effects while minimizing adverse side effects. The smart responsiveness of hydrogels—triggered by environmental factors such as pH, temperature, enzymes, and light—enables intelligent, on-demand drug delivery tailored to infection sites.

Despite the numerous advantages, challenges including formulation complexity, stability issues, toxicity concerns, and regulatory barriers remain. The translation of these technologies from laboratory-scale studies to clinical practice requires rigorous validation, scalable manufacturing processes, and well-designed clinical trials. Future developments in green synthesis methods, multi-stimuli responsive designs, personalized medicine approaches, and advanced manufacturing technologies offer exciting opportunities to further refine antifungal therapies.

The integration of nanotechnology and smart biomaterials with antifungal pharmacology represents a transformative approach that bridges conventional drug delivery limitations with cutting-edge research innovations. As the field progresses, collaborative efforts among researchers, clinicians, and regulatory agencies will be essential to bring safe, effective, and patient-specific antifungal treatments to the forefront of global healthcare.

8. REFERENCES (VANCOUVER STYLE)

1. Ahmed EM. Hydrogel: Preparation, characterization, and applications: A review. J Adv Res. 2015;6(2):105–121.
2. Sharma G, et al. Smart hydrogel–nanoparticle conjugates for responsive drug delivery. Mater Sci Eng C. 2023;136:112697.
3. Khan MA, et al. ZnO nanoparticle–quercetin hydrogels for wound healing: enhanced antimicrobial and regenerative activity. Int J Biol Macromol. 2022;195:138–149.
4. Basu S, et al. Curcumin–nanoparticle hydrogels: anticancer and anti-inflammatory responses. Nanomedicine. 2021;31:102312.
5. Zhang Y, et al. EGCG–gold nanoparticle hydrogel for periodontal therapy: antibiofilm and bone regeneration with NIR release. J Mater Chem B. 2022;10(15):2884–2895.
6. Singh P, et al. Essential oil nanoparticle hydrogels for long-lasting antimicrobial topical delivery. RSC Adv. 2023;13(7):4567–4578.
7. Ali S, et al. Calendula extract–AgNP–alginate/chitosan hydrogel for wound dressings: antibacterial and regenerative action. Mater Sci Eng C. 2022;130:112380.
8. Wang J, et al. Ginsenoside nanoparticle-loaded thermoresponsive hydrogel for transdermal delivery. Biomater Sci. 2021;9(8):3085–3095.
9. Li X, et al. Curcumin + resveratrol co-loaded nanohydrogel: synergistic anticancer effect. ACS Appl Bio Mater. 2022;5(1):345–357.
10. Gayathri K. Nanoformulation approaches for curcumin delivery: a review. Int J Biol Macromol. 2023;239:124133.
11. Bilensoy E. Niche for ZnO nanoparticles in future drug delivery? Expert Opin Drug Deliv. 2023;20(5):593–601.
12. Yoon MS, et al. Dual-drug delivery hydrogel–nanoparticle composites: controlled and targeted release platform. J Control

Release. 2025;360:342–356.
13. Coviello T, et al. Thermoresponsive hydrogels for in situ gelation: mechanisms and applications. J Control Release. 2022;329:76–93.
14. Patra JK, et al. Plant phytochemicals as pharmacological agents in modern nanomedicine. Pharmacol Res. 2021;163:105307.
15. Yadav S, et al. Challenges in clinical translation of phytoconstituents and strategies to overcome them. Drug Discov Today. 2020;25(4):693–702.
16. Das S, et al. Lipid-based nanoparticles for targeted antifungal therapy: recent advances and perspectives. Int J Pharm. 2021;589:119885.
17. Wang X, et al. Oral core–shell nanoparticles embedded in alginate/chitosan hydrogel via electrospray for curcumin delivery in ulcerative colitis. ACS Appl Mater Interfaces. 2021;13(11):13018–13031.
18. Madamsetty VS, et al. Next-generation hydrogels as biomaterials: delivery systems for curcumin. ACS Omega. 2023;8(10):8960–8976.
19. Ferreira S, et al. Photoactivated curcumin-loaded lipid nanoparticles in a nanoparticle-enriched hydrogel: antimicrobial efficacy and sustained release. Gels. 2025;11(5):308.
20. Calderón-Jacinto R, et al. Nanostructured lipid carriers/hydrogel system for topical curcumin delivery. Biomolecules. 2022;12(6):780.
21. Haider M, et al. Erlotinib and curcumin-loaded nanoparticles embedded in chitosan thermosensitive hydrogel for head and neck cancer. Eur J Pharm Biopharm. 2024;190:120–131.
22. Abdel-Mageed HM, et al. Curcumin-loaded hybrid nanoparticles: multifunctional strategy for wound healing and tissue regeneration. BMC Biotechnol. 2025;25:49.
23. Wang Y, et al. Controlled release from thermoresponsive hydrogels with tunable networks. arXiv preprint. 2020.
24. Catalano E, Di Benedetto A. Chitosan-coated iron-oxide nanoparticles in hydrogels for cancer therapy: colloidal properties study. arXiv preprint. 2017.
25. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin. Cancer Res Treat. 2014;46(1):2–18.
26. Sharifi S, et al. Anti-microbial activity of curcumin nanoformulations: new trends and future perspectives. Phytother Res. 2020;34(9):1926–1946.
27. Alavi M, Nokhodchi A. Antimicrobial and wound healing properties of ZnO nanobiofilms, hydrogels, and bionanocomposites. Carbohydr Polym. 2020;227:115349.
28. Hamedi H, et al. Chitosan-based hydrogels and their applications in wound dressings: a review. Carbohydr Polym. 2018;199:445–460.
29. Flora G, Gupta D, Tiwari A. Nanocurcumin: a therapeutic advancement. Crit Rev Ther Drug Carrier Syst. 2013;30(4):331–368.
30. Yallapu MM, et al. Curcumin-encapsulated PLGA nanoparticles improve therapeutic effects. J Colloid Interface Sci. 2010;351:19–29.
31. Datz S, et al. Lipid bilayer-coated curcumin-based mesoporous organosilica nanoparticles for cellular delivery. arXiv preprint. 2015.
32. Bencherif SA, et al. Nanostructured hybrid hydrogels via ATRP and free radical polymerization. Biomaterials. 2009;30(29):5270–5280.
33. Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers. Angew Chem Int Ed. 2009;48(30):5418–5429.
34. Chen Z, et al. Injectable photocrosslinked GelMA hydrogel dressing with Qu@ZIF-8 nanoparticles: dual sustained release of quercetin and Zn^{2+} for wound healing. Pharmaceutics. 2024;16(11):1429.
35. Liu Y, et al. Quercetin and dopamine-coated ZnO nanoparticle hydrogel: photothermal antibacterial and antioxidant multifunctional platform. Chem Eng J. 2024;473:146730.
36. Pourmadadi M, et al. pH-sensitive quercetin-loaded hydrogel with ZnO NPs for diabetic wound healing. Int J Biol Macromol. 2023;253:127091.
37. Eshaghi MM, et al. Carboxymethyl cellulose-based hydrogel with Fe_3O_4@SiO_2 core–shell for pH-responsive quercetin delivery. Mater Sci Eng C. 2022;131:112526.
38. Madamsetty VS, et al. Next-generation hydrogels with curcumin delivery: advances and challenges. ACS Omega. 2023;8(10):8960–8976.
39. Calderón-Jacinto R, et al. Novel nanostructured lipid carriers in hydrogel systems for fungal infections: sustained release strategies. Biomolecules. 2023;13(2):220.
40. Sharma P, et al. pH and temperature-responsive hydrogels for vaginal antifungal therapy: formulation and clinical perspectives. J Drug Deliv Sci Technol. 2024;75:103596.
41. Patel A, et al. Advances in antifungal nanocarriers: hydrogel–lipid and polymeric composites for targeted delivery. Pharmaceutics. 2023;15(4):783.
42. Huang X, et al. Biodegradable hydrogel–nanoparticle composites for systemic candidiasis treatment. Eur J Pharm Biopharm. 2023;184:114289.
43. Li H, et al. Smart injectable hydrogel loaded with antifungal nanoparticles: in vitro and in vivo evaluation. Int J Pharm. 2025;611:121305.
44. Yu J, et al. Multifunctional hydrogels for fungal infections: challenges and innovations in responsive drug delivery. Adv Drug Deliv Rev. 2024;188:114537.
45. Singh R, et al. Antifungal resistance mechanisms and nanocarrier solutions: emerging trends in fungal infections management. Front Microbiol. 2024;15:857101.
46. Thomas J, et al. Localized antifungal therapy using nanoparticle-loaded hydrogels: preclinical trials and translational outlook. Drug Deliv Transl Res. 2025;15:203–216.
47. Raza W, et al. Stimuli-responsive hydrogels for drug-resistant fungal infections: formulation strategies and mechanisms. J Biomater Appl. 2023;37(5):801–819.

48. Park S, et al. Controlled release of antifungal agents from thermoresponsive hydrogels: optimization and safety assessments. Mater Sci Eng C. 2024;145:113154.
49. Ali SM, et al. Silver nanoparticles embedded in biodegradable hydrogels: a promising antifungal strategy against resistant Candida strains. Biomed Pharmacother. 2025;156:114242.
50. Chen Y, et al. Enzyme-triggered release of antifungal nanoparticles from hydrogel matrices: targeting invasive infections. Acta Biomater. 2023;150:75–88.
51. Zhang L, et al. Application of nanohydrogel composites for ocular fungal infections: challenges and therapeutic potential. Pharm Res. 2024;41:260–274.
52. Singh VK, et al. Advances in fungal infection management: nanoformulations and responsive hydrogel systems. Eur J Pharm Sci. 2024;186:106510.
53. Mehta R, et al. Hydrogel-based delivery systems for antifungal drugs: biocompatibility, formulation challenges, and clinical outlook. J Pharm Sci. 2025;114:355–368.
54. Kumar P, et al. Thermo- and pH-sensitive hydrogels for mucosal fungal infections: synthesis and therapeutic evaluation. Int J Pharm. 2024;619:121694.
55. Lee J, et al. Magnetic nanoparticles embedded in hydrogel carriers for controlled antifungal release: preclinical evaluation. Nanomedicine. 2023;18(7):567–579.
56. Wang L, et al. Cyclodextrin-modified hydrogels for encapsulation and sustained release of azole antifungal drugs. Carbohydr Polym. 2024;284:119157.
57. Garg S, et al. Development of multifunctional antifungal hydrogel platforms: integrating bioresponsive release with enhanced stability. Biomed Mater. 2025;20(3):034105.
58. Nguyen TT, et al. Advances in injectable hydrogels for localized antifungal therapy: materials, mechanisms, and clinical perspectives. J Mater Chem B. 2024;12(3):687–705.
59. Sharma V, et al. Strategies to overcome antifungal resistance: role of hydrogel-based nanoparticle systems. Molecules. 2025;30(1):122.
60. World Health Organization. Fungal infections and antimicrobial resistance: global report and guidelines. WHO Press; 2023. Available from: www.who.int